QuidelOrtho reports 12% revenue decline and narrows 2026 guidance
FROM THE WIRE · PRNEWSWIRE.COM
― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ― ― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ― ― Updated Full-Year 2026 Financial Guidance Narrowing…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishRevenue decline partly offset by a savings plan, with full-year guidance narrowed.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third quarter 2026 revenue was $619 million, down 12%.
- 02The new cost transformation program is expected to deliver over $80 million in annual savings in 2027.
- 03Full-year 2026 guidance was updated with narrower ranges.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets